Market Research Logo

Global Dengue Vaccines Market Insights, Opportunity Analysis, Market Shares and Forecast, 2017 - 2023

Global Dengue Vaccines Market Insights, Opportunity Analysis, Market Shares and Forecast, 2017 - 2023

Dengue fever is the mosquito borne tropical disease caused by dengue virus which is spread by several species of Aedes aegypti type mosquito. Dengue vaccine is used to prevent dengue fever in human beings. The global dengue vaccine market is expected to grow at a CAGR of about 18 % during the forecast period 2016-2023. The dengue vaccine currently available is used to prevent slow dengue only. Due to this, there is a large demand for best efficient drugs and vaccines for dengue. Also majority of the key market players are joining hands together to completely eradicate dengue fever from the entire world. The key driver fuelling the growth of global dengue vaccine market is the increasing number of occurrences of dengue fever.

Dengue is a deadly disease which is continuously spreading over the globe. Countries such as Brazil, Singapore, India are the leading market for dengue vaccine. Also, there is increasing demand for dengue vaccines in North America due to large number of dengue cases. In the America, nearly 500 million people are at risk of contracting the disease. The revenue growth of the dengue vaccine market is due to the adoption of dengue vaccine by various countries in dengue endemic regions of Latin America and Asia Pacific and due to increase in governmental interest to deploy the dengue vaccine in public immunization programs across several countries.

The global dengue vaccine market is influenced by the presence of leading dengue vaccine manufacturers such as Sanofi Pasteur [France], Takeda [ Japan], Xenetic Biosciences [UK], Merck and Co. [U.S.], Johnson and Johnson [U.S] and others. Product launches, Joint ventures, Mergers and acquisitions are some of the crucial strategies adopted by the key market players to gain competitive advantage.

Global dengue vaccine market report is segmented on the basis of product type, technology type and end users. The Government Institutes segment is expected to account for 50% revenue share in 2017 and is expected to account for 51.9% revenue share by the end of 2023. This segment is expected to lead the global dengue vaccine market in revenue terms and it is going to continue its dominance throughout the forecast period. The Hospitals segment is expected to grow at a CAGR of 17.3% during the forecast period. The NGOs segment is estimated to hold 23% revenue share in 2017 and is expected to account for 21 % market value share by the end of 2023.

Please note: The delivery time for the electronic version of this report is between 1-3 business days to allow the preparation of an updated version prior to dispatch.


1. INTRODUCTION
1.1. EXECUTIVE SUMMARY
1.2. ESTIMATION METHODOLOGY
2. MARKET OVERVIEW
2.1. GLOBAL DENGUE VACCINE MARKET: EVOLUTION & TRANSITION
2.2. MARKET DEFINITION & SCOPE
2.3. INDUSTRY STRUCTURE
2.4. REGULATORY FRAMEWORK
2.5. TOTAL MARKET ANALYSIS
2.5.1. TOP 5 FINDINGS
2.5.2. TOP 5 OPPORTUNITY MARKETS
2.5.3. TOP 5 COMPANIES
2.5.4. TOP 3 COMPETITIVE STRATEGIES
2.6. ESTIMATION ANALYSIS
2.7. STRATEGIC ANALYSIS
2.7.1. INVESTMENT VS. ADOPTION MODEL
2.7.2. 360-DEGREE INDUSTRY ANALYSIS
2.7.3. PORTER'S 5 FORCE MODEL
2.7.4. SEE-SAW ANALYSIS
2.7.5. CONSUMER ANALYSIS AND KEY BUYING CRITERIA
2.8. COMPETITIVE ANALYSIS
2.8.1. KEY STRATEGIES & ANALYSIS
2.8.2. MARKET SHARE ANALYSIS AND TOP COMPANY ANALYSIS
2.9. STRATEGIC RECOMMENDATIONS & KEY CONCLUSIONS
2.9.1. INVESTMENT OPPORTUNITIES BY REGIONS
2.9.2. OPPORTUNITIES IN EMERGING APPLICATIONS
2.9.3. INVESTMENT OPPORTUNITY IN FASTEST GROWING SEGMENT
3. MARKET DETERMINANTS
3.1. MARKET DRIVERS
3.1.1. INCREASING NUMBER OF DENGUE CASES
3.1.2. INCREASING DEMAND FOR EFFECTIVE VACCINES
3.1.3. DEVELOPMENT OF LIVE ATTENUATED VACCINES
3.1.4. KEEN INTEREST SHOWN BY COMPANIES FOR THE COMBAT OF THE DISEASE
3.2. MARKET RESTRAINTS
3.2.1. LACK OF GOVERNMENT FACILITIES
3.2.2. UNAVAILABILITY OF OPTIMUM DIAGNOSTIC SYSTEMS
3.3. MARKET OPPORTUNITIES
3.3.1. DEVELOPMENT OF DENGUE VACCINE FOR ALL AGE GROUPS
3.3.2. DEVELOPMENT OF SINGLE DOSE DENGUE VACCINE
3.4. MARKET CHALLENGES
3.4.1. HIGH COST OF VACCINES
3.4.2. LACK OF SKILLED WORKFORCE
4. MARKET SEGMENTATION
4.1. GLOBAL DENGUE VACCINE MARKET BY PRODUCT TYPE
4.1.1. MARKET DEFINITION AND SCOPE
4.1.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.1.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.1.4. OPPORTUNITY MATRIX
4.1.5. MARKET SEGMENTATION
4.1.5.1. GLOBAL CYD-TDV (DENGVAXIA) MARKET
4.1.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.5.1.3. TOP PLAYERS & KEY PRODUCTS
4.1.5.1.4. KEY CONCLUSIONS
4.2. GLOBAL DENGUE VACCINE MARKET BY TECHNOLOGY
4.2.1. MARKET DEFINITION AND SCOPE
4.2.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.2.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.2.4. OPPORTUNITY MATRIX
4.2.5. MARKET SEGMENTATION
4.2.5.1. GLOBAL LIVE ATTENUATED VACCINE MARKET
4.2.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.1.3. TOP PLAYERS & KEY PRODUCTS
4.2.5.1.4. KEY CONCLUSIONS
4.2.5.2. GLOBAL CHIMERIC LIVE ATTENUATED VACCINE MARKET
4.2.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.2.3. TOP PLAYERS & KEY PRODUCTS
4.2.5.2.4. KEY CONCLUSIONS
4.2.5.3. GLOBAL INACTIVATED VACCINE MARKET
4.2.5.3.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.3.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.3.3. TOP PLAYERS & KEY PRODUCTS
4.2.5.3.4. KEY CONCLUSIONS
4.2.5.4. GLOBAL SUBUNIT VACCINE MARKET
4.2.5.4.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.4.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.4.3. TOP PLAYERS & KEY PRODUCTS
4.2.5.4.4. KEY CONCLUSIONS
4.2.5.5. GLOBAL NUCLEIC ACID BASED VACCINE MARKET
4.2.5.5.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.5.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.5.3. TOP PLAYERS & KEY PRODUCTS
4.2.5.5.4. KEY CONCLUSIONS
4.3. GLOBAL DENGUE VACCINE MARKET BY END USERS
4.3.1. MARKET DEFINITION AND SCOPE
4.3.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.3.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.3.4. OPPORTUNITY MATRIX
4.3.5. MARKET SEGMENTATION
4.3.5.1. GLOBAL HOSPITAL MARKET
4.3.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.1.3. TOP PLAYERS & KEY PRODUCTS
4.3.5.1.4. KEY CONCLUSIONS
4.3.5.2. GLOBAL GOVERNMENT INSTITUTES MARKET
4.3.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.2.3. TOP PLAYERS & KEY PRODUCTS
4.3.5.2.4. KEY CONCLUSIONS
4.3.5.3. GLOBAL NON GOVERNMENT ORGANIZATION MARKET
4.3.5.3.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.3.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.3.3. TOP PLAYERS & KEY PRODUCTS
4.3.5.3.4. KEY CONCLUSIONS
5. COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES
5.1.1. LIST OF MERGERS AND ACQUISITION
5.1.2. LIST OF JOINT VENTURES
5.1.3. LIST OF PRODUCT LAUNCHES
5.1.4. LIST OF PARTNERSHIPS
6. GEOGRAPHICAL ANALYSIS
6.1. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
6.2. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
6.3. OPPORTUNITY MATRIX
6.4. GLOBAL DENGUE VACCINES MARKET BY REGION 2014-2023 ($ MILLION)
6.4.1. NORTH AMERICA
6.4.1.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
6.4.1.2. TOP COUNTRY ANALYSIS
6.4.1.2.1. U.S.
6.4.1.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.1.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.1.2.1.3. KEY CONCLUSIONS
6.4.1.2.2. CANADA
6.4.1.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.1.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.1.2.2.3. KEY CONCLUSIONS
6.4.2. EUROPE
6.4.2.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
6.4.2.2. TOP COUNTRY ANALYSIS
6.4.2.2.1. UK
6.4.2.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.1.3. KEY CONCLUSIONS
6.4.2.2.2. FRANCE
6.4.2.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.2.3. KEY CONCLUSIONS
6.4.2.2.3. GERMANY
6.4.2.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.3.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.3.3. KEY CONCLUSIONS
6.4.2.2.4. SPAIN
6.4.2.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.4.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.4.3. KEY CONCLUSIONS
6.4.2.2.5. REST OF EUROPE
6.4.2.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.5.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.5.3. KEY CONCLUSIONS
6.4.3. ASIA PACIFIC
6.4.3.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
6.4.3.2. TOP COUNTRY ANALYSIS
6.4.3.2.1. CHINA
6.4.3.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.1.3. KEY CONCLUSIONS
6.4.3.2.2. INDIA
6.4.3.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.2.3. KEY CONCLUSIONS
6.4.3.2.3. JAPAN
6.4.3.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.3.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.3.3. KEY CONCLUSIONS
6.4.3.2.4. AUSTRALIA
6.4.3.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.4.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.4.3. KEY CONCLUSIONS
6.4.3.2.5. REST OF ASIA PACIFIC
6.4.3.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.5.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.5.3. KEY CONCLUSIONS
6.4.4. ROW
6.4.4.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
6.4.4.2. TOP COUNTRY ANALYSIS
6.4.4.2.1. LATIN AMERICA
6.4.4.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.4.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.4.2.1.3. KEY CONCLUSIONS
6.4.4.2.2. MIDDLE EAST & AFRICA
6.4.4.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.4.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.4.2.2.3. KEY CONCLUSIONS
7. COMPANY PROFILES
7.1 SANOFI PASTEUR (FRANCE.)
7.1.1. OVERVIEW
7.1.2. PRODUCT PORTFOLIO
7.1.3. KEY INNOVATION SECTOR
7.1.4. STRATEGIC INITIATIVES
7.1.5. SCOT ANALYSIS
7.1.6. STRATEGIC ANALYSIS
7.2 PANACEA BIOTECH (INDIA)
7.1.7. OVERVIEW
7.1.8. PRODUCT PORTFOLIO
7.1.9. KEY INNOVATION SECTOR
7.1.10. STRATEGIC INITIATIVES
7.1.11. SCOT ANALYSIS
7.1.12. STRATEGIC ANALYSIS
7.3 BIOLOGICAL E. LIMITED (INDIA)
7.3.1 OVERVIEW
7.3.2 PRODUCT PORTFOLIO
7.3.3 KEY INNOVATION SECTOR
7.3.4 STRATEGIC INITIATIVES
7.3.5 SCOT ANALYSIS
7.3.6 STRATEGIC ANALYSIS
7.4 VABIOTECH VACCINES CENTER (VIETNAM)
7.4.1 OVERVIEW
7.4.2 PRODUCT PORTFOLIO
7.4.3 KEY INNOVATION SECTOR
7.4.4 STRATEGIC INITIATIVES
7.4.5 SCOT ANALYSIS
7.4.6 STRATEGIC ANALYSIS
7.5 SUN PHARMA (INDIA )
7.5.1 OVERVIEW
7.5.2 PRODUCT PORTFOLIO
7.5.3 KEY INNOVATION SECTOR
7.5.4 STRATEGIC INITIATIVES
7.5.5 SCOT ANALYSIS
7.5.6 STRATEGIC ANALYSIS
7.6 ICGEB (INDIA.)
7.6.1 OVERVIEW
7.6.2 PRODUCT PORTFOLIO
7.6.3 KEY INNOVATION SECTOR
7.6.4 STRATEGIC INITIATIVES
7.6.5 SCOT ANALYSIS
7.6.6 STRATEGIC ANALYSIS
7.7 XENETIC BIOSCIENCES (U.K.)
7.7.1 OVERVIEW
7.7.2 PRODUCT PORTFOLIO
7.7.3 KEY INNOVATION SECTOR
7.7.4 STRATEGIC INITIATIVES
7.7.5 SCOT ANALYSIS
7.7.6 STRATEGIC ANALYSIS
7.8 TAKEDA PHARMACEUTICAL COMPANY (JAPAN)
7.8.1 OVERVIEW
7.8.2 PRODUCT PORTFOLIO
7.8.3 KEY INNOVATION SECTOR
7.8.4 STRATEGIC INITIATIVES
7.8.5 SCOT ANALYSIS
7.8.6 STRATEGIC ANALYSIS
7.9 MERCK & CO. (U.S.)
7.9.1 OVERVIEW
7.9.2 PRODUCT PORTFOLIO
7.9.3 KEY INNOVATION SECTOR
7.9.4 STRATEGIC INITIATIVES
7.9.5 SCOT ANALYSIS
7.9.6 STRATEGIC ANALYSIS
7.10 GLAXOSMITHKLINE PLC (U.K.)
7.10.1 OVERVIEW
7.10.2 PRODUCT PORTFOLIO
7.10.3 KEY INNOVATION SECTOR
7.10.4 STRATEGIC INITIATIVES
7.10.5 SCOT ANALYSIS
7.10.6 STRATEGIC ANALYSIS
7.11 BUTANTAN INSTITUTE (BRAZIL)
7.11.1 OVERVIEW
7.11.2 PRODUCT PORTFOLIO
7.11.3 KEY INNOVATION SECTOR
7.11.4 STRATEGIC INITIATIVES
7.11.5 SCOT ANALYSIS
7.11.6 STRATEGIC ANALYSIS
7.12 PFIZER (U.S.)
7.12.1 OVERVIEW
7.12.2 PRODUCT PORTFOLIO
7.12.3 KEY INNOVATION SECTOR
7.12.4 STRATEGIC INITIATIVES
7.12.5 SCOT ANALYSIS
7.12.6 STRATEGIC ANALYSIS
7.13 JOHNSON & JOHNSON (U.S.)
7.13.1 OVERVIEW
7.13.2 PRODUCT PORTFOLIO
7.13.3 KEY INNOVATION SECTOR
7.13.4 STRATEGIC INITIATIVES
7.13.5 SCOT ANALYSIS
7.13.6 STRATEGIC ANALYSIS
7.14 NOVARTIS PHARMACEUTICAL (SWITZERLAND)
7.14.1 OVERVIEW
7.14.2 PRODUCT PORTFOLIO
7.14.3 KEY INNOVATION SECTOR
7.14.4 STRATEGIC INITIATIVES
7.14.5 SCOT ANALYSIS
7.14.6 STRATEGIC ANALYSIS
7.15 ROCHE LIFE SCIENCE (SWITZERLAND)
7.15.1 OVERVIEW
7.15.2 PRODUCT PORTFOLIO
7.15.3 KEY INNOVATION SECTOR
7.15.4 STRATEGIC INITIATIVES
7.15.5 SCOT ANALYSIS
7.15.6 STRATEGIC ANALYSIS
LIST OF TABLES
GLOBAL DENGUE VACCINES MARKET BY PRODUCT TYPE 2014-2023 ($ MILLION)
GLOBAL CYD-TDV (DENGVAXIA) MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL DENGUE VACCINE MARKET BY TECHNOLOGY 2014-2023 ($ MILLION)
GLOBAL LIVE ATTENUATED VACCINE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL CHIMERIC LIVE ATTENUATED VACCINE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL INACTIVATED VACCINE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL SUBUNIT VACCINE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL NUCLEIC ACID BASED VACCINE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL DENGUE VACCINE MARKET BY END USERS 2014-2023 ($ MILLION)
GLOBAL HOSPITAL MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL GOVERNMENT INSTITUTES MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL NON GOVERNMENT ORGANIZATION MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
NORTH AMERICA DENGUE VACCINES MARKET 2014-2023 ($ MILLION)
EUROPE DENGUE VACCINES MARKET 2014-2023 ($ MILLION)
ASIA PACIFIC DENGUE VACCINES MARKET 2014-2023 ($ MILLION)
REST OF THE WORLD DENGUE VACCINES MARKET 2014-2023 ($ MILLION)
LIST OF FIGURES
GLOBAL DENGUE VACCINES MARKET BY PRODUCT TYPE 2014-2023 ($ MILLION)
GLOBAL CYD-TDV (DENGVAXIA) MARKET 2014-2023 ($ MILLION)
GLOBAL DENGUE VACCINE MARKET BY TECHNOLOGY 2014-2023 ($ MILLION)
GLOBAL LIVE ATTENUATED VACCINE MARKET 2014-2023 ($ MILLION)
GLOBAL CHIMERIC LIVE ATTENUATED VACCINE MARKET 2014-2023 ($ MILLION)
GLOBAL INACTIVATED VACCINE MARKET 2014-2023 ($ MILLION)
GLOBAL SUBUNIT VACCINE MARKET 2014-2023 ($ MILLION)
GLOBAL NUCLEIC ACID BASED VACCINE MARKET 2014-2023 ($ MILLION)
GLOBAL DENGUE VACCINE MARKET BY END USERS 2014-2023 ($ MILLION)
GLOBAL HOSPITAL MARKET 2014-2023 ($ MILLION)
GLOBAL GOVERNMENT INSTITUTES MARKET 2014-2023 ($ MILLION)
GLOBAL NON GOVERNMENT ORGANIZATION MARKET 2014-2023 ($ MILLION)
UNITED STATES (U.S.) DENGUE VACCINES MARKET 2014-2023 ($ MILLION)
CANADA DENGUE VACCINES MARKET 2014-2023 ($ MILLION)
UNITED KINGDOM (UK) DENGUE VACCINES MARKET 2014-2023 ($ MILLION)
FRANCE DENGUE VACCINES MARKET 2014-2023 ($ MILLION)
GERMANY DENGUE VACCINES MARKET 2014-2023 ($ MILLION)
SPAIN DENGUE VACCINES MARKET 2014-2023 ($ MILLION)
ROE DENGUE VACCINES MARKET 2014-2023 ($ MILLION)
INDIA DENGUE VACCINES MARKET 2014-2023 ($ MILLION)
CHINA DENGUE VACCINES MARKET 2014-2023 ($ MILLION)
JAPAN DENGUE VACCINES MARKET 2014-2023 ($ MILLION)
AUSTRALIA DENGUE VACCINES MARKET 2014-2023 ($ MILLION)
ROAPAC DENGUE VACCINES MARKET 2014-2023 ($ MILLION)
LATIN AMERICA DENGUE VACCINES MARKET 2014-2023 ($ MILLION)
MENA DENGUE VACCINES MARKET 2014-2023 ($ MILLION)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report